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ABSTRACT 
Stability indicating RP-HPLC method was developed for the simultaneous quantitation of 
Sofosbuvir and Velpatasvir in its pharmaceutical dosage form and validated. The drugs were 
separated on Discovery C18 (150mm x 4.6mm, 5µ) column using 0.01N potassium 
dihydrogen phosphate buffer and acetonitrile (50:50%v/v) as mobile phase on isocratic mode. 
The mobile phase is pump into the column at flow rate of 1.0ml/min and column oven 
temperature is maintained at 30ºC. The drugs were detected at a wavelength 240nm. The 
retention time for Sofosbuvir and Velpatasvir were found to be 2.32min and 3.34min 
respectively. The developed method is validated in accordance with ICH guidelines. The 
method was found to be accurate, precise, specific and robust. The method obeys Beer’s law 
at a concentration range of 100µg/ml – 600µg/ml of Sofosbuvir and 25µg/ml – 150µg/ml of 
Velpatasvir, with correlation coefficient of 0.999 for both the drugs. The drugs were found to 
be stable and less prone to degradation when they are subjected to various stress conditions.
Introduction 
 
Sofosbuvir (Figure 1A) chemically is Isopropyl (2S)-2-
[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3 
hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-
phosphoryl]amino]propanoate. It is white to off-white 
crystalline solid, slightly soluble in water with a pKa value of 
9.38. It is an antiviral drug used in the treatment of Hepatitis C 
[1,2]. Velpatasvir (Figure 1B) chemically is Methyl {(2S)-1-
[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl) 
amino]-2-phenylacetyl}-4(methoxymethyl)-2-pyrrolidinyl]-
1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7] 
naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-
methyl-1-oxo-2-butanyl}carbamate. It is white to tan or 
yellow hygroscopic solid, soluble in water, methanol and 
acetonitrile with pKa values of 3.72 and 5.98. It is an antiviral 
drug used to treat chronic hepatitis C [3,4]. The literature 
survey reveals that there is only one method i.e., RP-HPLC 
method [5] was developed for the simultaneous estimation of 
Sofosbuvir and Velpatasvir in pharmaceutical dosage from. 
The present study aimed to develop and validate a stability 
indicating method for the simultaneous determination of 
Sofosbuvir and Velpatasvir in the pharmaceutical dosage form 
using RP-HPLC. 
 
 
Figure 1A :Sofosbuvir 
 
Figure 1B: Velpatasvir 
 
 
          CODEN (USA): IJPB07                                                                     ISSN: 2320-9267   
                                                                    
Indian Journal of Pharmaceutical and Biological Research (IJPBR) 
Journal homepage: www.ijpbr.in 
Bandla and Ganapati / Indian J. Pharm. Biol. Res., 2017; 5(4):10-16 
 
Research Article  11 
 
Material and Methods 
 
Chemicals and reagents 
 Sofosbuvir standard drug and Velpatasvir standard drug were 
supplied as gift samples by Spectrum labs, Hyderabad. The 
Sofosbuvir and Velpatasvir tablets (Velpanat) were purchased 
from local pharmacy. The chemicals used for development of 
the method were of AR grade and purchased from Sigma 
Aldrich. The solvents used were of HPLC grade and 
purchased from Merck.  
Instrument and chromatographic conditions 
Waters HPLC system with Discovery C18 (150mm x 4.6mm, 
5µ) column, autosampler and PDA detection mode running on 
empower 2 software was used. An isocratic mode with 0.01N 
potassium dihydrogen phosphate buffer and acetonitrile in 1:1 
as mobile phase at 1.0ml/min flow rate was used for 
separation of drugs. The detection of drugs was done at 240nm 
with column oven temperature maintained at 30ºC. The other 
instruments used were pH meter (EI), Digital Balance (Infra 
Instruments), Ultrasonic Bath (Wadegati), Hot air oven 
(Cisco).  
Preparation of diluent: Water and acetonitrile in the ratio 1:1 
were mixed and used as diluent.  
Preparation of standard and sample solution: Dissolve an 
accurately weighed 40mg of Sofosbuvir working standard and 
10mg of Velpatasvir working standard in 10ml of diluent. 
Dilute 1ml of above solution with 10ml of diluent.   
Average weight was calculated for 20 tablets (Velpanat) and 
an amount equivalent to 40mg of Sofosbuvir was taken into 
10mL volumetric flask. The sample was dissolved in 10mL of 
diluent. The above solution was filtered using HPLC filters. 
Pipette out 1mL of the above solution into 10mL volumetric 
flask and made up with diluent. 
Method Validation 
The developed method was validated in accordance with ICH 
guidelines [6]. 
System suitability: Inject standard solution into the 
chromatographic system and calculate the parameters such as 
% relative standard deviation (RSD), tailing factor, plate count 
and resolution. 
Linearity: Serial dilutions of standard Sofosbuvir and 
Velpatasvir in the range of 100µg/mL - 600µg/mL and 
25µg/mL - 150µg/mL respectively were prepared and injected 
into the HPLC. A linearity graph was plotted between 
concentration and peak areas.  
Accuracy: The solutions were prepared in three different 
concentration levels of 50%, 100% and 150%, injected into 
HPLC and % recoveries were calculated.  
Precision: The precision of the method was determined by 
injecting the standard solution six times into HPLC and the % 
RSD was calculated. 
Specificity: The specificity of the method was determined by 
injecting the placebo solution and comparing with standard 
solution for the interference with Sofosbuvir andVelpatasvir 
peak.  
Limit of Detection (LOD) and Limit of Quantitation 
(LOQ): LOD and LOQ are determined by standard deviation 
(SD) and slope of the calibration curve. The limiting values 
are calculated as per the following equations: LOD = (3.3 × 
SD)/ Slope and LOQ = (10 × SD)/ Slope. 
Robustness: Robustness of the method was determined by 
varying the optimum chromatographic conditions such as 
mobile phase ratio (±10%), flow rate (±0.2mL/min) and 
column oven temperature (±5ºC). The system suitability 
parameters were calculated and recorded.   
Forced degradation studies: The drugs solution was 
subjected to the various stress conditions such as acidic (2N 
Hydrochloric acid, 60 ºC for 30 mins), basic (2N sodium 
hydroxide, 60 ºC for 30 mins), oxidative (20% hydrogen 
peroxide, 60 ºC for 30 mins), neutral 
(refluxingthedrugsinwaterfor6hrsatatemperature of 60ºC), 
photolytic (exposing the drugs solution to UV light by keeping 
the beaker in UV Chamber for 7 days or 200Watt hours/m
2 
in 
photo stability chamber) and thermal (drugs solution was 
placed in an oven at 105ºC for 6 hours) conditions.  
Results and Discussion 
Initially various mobile phases and columns were tried to elute 
the drugs. Discovery C18 (150mm x 4.6mm, 5µ) column, 
mobile phase consisting of 0.01N Potassium dihydrogen 
phosphate and Acetonitrile (50:50) on isocratic mode at flow 
rate 1.0ml/min was used to separate the drugs. The detection 
wavelength was selected from the overlay UV spectrum and 
was found to be 240nm as shown in Figure 2.  
 
Fig.2: Overlay UV spectrum of Sofosbuvir and Velpatasvir 
The standard solution, sample solution and blank solution were prepared and injected into the HPLC system. The standard, sample and 
blank chromatograms were shown in Figures 3, 4 and 5 respectively. 
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Fig.3: Standard Chromatogram                                \ 
 
Fig.4: Sample Chromatogram 
 
Fig.5: Blank Chromatogram 
 The linearity of the method was determined by preparing serial dilutions of Sofosbuvir and Velpatasvir in the concentration range of 
100µg/ml – 600µg/ml and 25µg/ml – 150µg/ml respectively. A linear response was observed in the above concentration ranges with a 
correlation coefficient of 0.999. The linearity plots were shown in Figure 6A and 6B. 
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Fig.6A: Linearity plot of Sofosbuvir 
 
Fig.6B: Linearity plot of Velpatasvir 
The % RSD was found to be 0.3 for Sofosbuvir and 0.8 for Velpatasvir and % recovery was found to be 99.58% - 100.13% for 
Sofosbuvir and 99.80% - 100.45% for Velpatasvir, indicating the method to be accurate and precise. The method was found to 
berugged, robust and stable up to 24 hours. The developed method was found to be specific for the drugs, as there is no interference of 
placebo peaks with the retention time of drugs. The placebo chromatogram was shown in figure 7.The system suitability parameters 
and validation parameters results are summarized in table 1.  
 
Fig.7: Placebo chromatogram 
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Table No. 1 : System suitability and validation parameters 
 
Parameter Sofosbuvir Velpatasvir 
Specificity Specific, No interference Specific, No interference 
Precision (% RSD) 0.3 0.8 
Accuracy (% Recovery) 99.58% - 100.13% 99.80% - 100.45% 
Linearity range (µg/mL) 100 – 600 25 – 150 
Correlation coefficient, r 0.9997 0.9997 
Limit of Detection (µg/mL) 0.26 0.17 
Limit of Quantitation (µg/mL) 0.78 0.50 
Ruggedness (% RSD) 0.6 0.5 
Robustness Robust Robust 
Stability Stable Stable 
USP Plate Count 4913 7145 
USP Tailing factor 1.13 1.01 
USP Resolution 6.8 
The forced degradation studies were conducted by exposing the standard solution to the various stress conditions. The net degradation 
was found to be within the limits, indicates that the drugs are stable at various stress conditions. The forced degradation studies results 
were summarized in table 2 and chromatograms were shown in figure 8. 
 
Table 2: Forced degradation studies results 
 
S.No. Stress condition Sofosbuvir Velpatasvir % area of 
degradation 
peak % Assay Peak purity 
Angle 
Peak 
purity 
threshold 
% 
Assay 
Peak 
purity 
angle 
Peak purity 
threshold 
1 2N HCL for 30mins at 60°C 95.21 0.185 0.285 95.03 0.286 0.291 - 
2 2N NaOH for 30mins  at 60°C 97.21 0.172 0.237 97.34 0.242 0.283 - 
3 20% H2O2 for 30mins at 60
0
C 98.04 0.310 0.402 98.33 0.209 0.308 - 
4 Water for 6hrs at60
0
C 99.19 0.130 0.290 99.04 0.142 0.308 - 
5 UV light 200wts/hr or 7 days 99.41 0.126 0.288 99.24 0.129 0.302 - 
6 105
0
C for 6hrs 99.16 0.211 0.287 99.49 0.100 0.297 - 
 
Fig.8A: Acid degradation chromatogram 
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Fig.8B: Base degradation chromatogram 
 
Fig.8C: Peroxide degradation chromatogram 
 
Fig.8D: Water stress study chromatogram 
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Fig.8E: Photo stability degradation chromatogram 
 
Fig.8F: Dry heat study chromatogram 
Conclusion 
 
Stability indicating RP-HPLC method was developed for the 
simultaneous estimation of Sofosbuvir and Velpatasvir in 
pharmaceutical dosage form. The developed method was 
validated and found to be specific, accurate, precise, linear and 
robust. The drugs, Sofosbuvir and Velpatasvir were stable 
under different forced degradation conditions.  The developed 
method can be used for the rapid quantification of Sofosbuvir 
and Velpatasvir in its pharmaceutical dosage form. 
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